ARCHIVES

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

This article is from The Cancer Letter archive.

Vol. 33 No. 27 | July 13, 2007

Download PDF Visit The Full Archive

Related Articles

Long-term Hormonal Therapy Adds No Additional Benefits

September 27, 2013

Senate Confirms Kansas Gov. Sebelius For HHS Secretary

May 1, 2009

AACR Plans Office in Singapore.

November 30, 2007

H. Lee Moffitt Center Reads The Cancer Letter

July 19, 2002

Huebner Retires, Named Scientist Emeritus

November 19, 1982

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

November 26, 2010